NewLink Genetics Corporation
Aug 29, 2017

NewLink Genetics to Participate in Upcoming Investor Conferences

AMES, Iowa, Aug. 29, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September:

A live webcast of both conference presentations will be on the Company's website at in the "Investors & Media" section under "Events and Presentations."

About NewLink Genetics Corporation

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including PD-1 checkpoint blockade, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visit

Investor Contact:

Lisa Miller

Director of Investor Relations

NewLink Genetics

(515) 598-2555

Media Contact:

Andrew Mastrangelo

AVP, Public & Media Relations


617-374-8800, ext. 108

Primary Logo

Source: NewLink Genetics Corporation

News Provided by Acquire Media